Press Releases

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 8, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 27 th Annual Credit Suisse Healthcare Conference on Wednesday, November 14 th , 2018 at 2:15 p.m. Mountain Time ( 4:15 p.m.

– LINZESS ® (linaclotide) U.S. net sales increased 7% to $205 million in 3Q 2018 vs 3Q 2017 – – Ironwood revenue of $66 million in 3Q 2018, which includes a $30 million reduction due to LINZESS change in estimate as reported to Ironwood by Allergan – – Received Fast Track Designation for

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 25, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its third quarter 2018 investor update conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, November 6, 2018 . Individuals interested in participating in the

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 8, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced the presentation of clinical data for IW-3718 and linaclotide from the company and its collaborators during the American College of Gastroenterology

– Praliciguat Phase II trial in HFpEF continues to enroll patients with topline data expected in the second half of 2019 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 13, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced that the U.S.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 28, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present corporate updates at two upcoming investor conferences in September: 2018 Wells Fargo Healthcare Conference on Thursday, September 6, 2018 at 1:55 p.m.

TOKYO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 21, 2018-- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., “Astellas” ) and Ironwood Pharmaceuticals, Inc (Nasdaq: IRWD , “Ironwood”) today announced that approval has been obtained in Japan for the guanylate cyclase-C

– Second quarter revenue increased 25% year-over-year to $81 million , driven primarily by LINZESS ® (linaclotide) U.S. net sales of $192 million and commercial margin of 60% – – Terminating licensing agreement with AstraZeneca for U.S. lesinurad franchise – – Initiated Phase III programs with

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 23, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its second quarter 2018 investor update conference call and webcast at 8:30 a.m. Eastern Time on Monday, August 6, 2018 . Individuals interested in participating in the

– Trial designed to more comprehensively evaluate the effect of linaclotide 290 mcg on bothersome abdominal symptoms, including bloating, discomfort and pain, associated with IBS-C – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 16, 2018-- Ironwood Pharmaceuticals, Inc.

– Data provide additional evidence supporting development of praliciguat as a potential treatment for diabetic nephropathy and for heart failure with preserved ejection fraction – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 23, 2018-- Ironwood Pharmaceuticals, Inc.

– Program Designed to Support U.S. Regulatory Filing of IW-3718 as Potential Treatment for Patients Who Continue to Suffer From GERD Despite Receiving Standard of Care – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 21, 2018-- Ironwood Pharmaceuticals, Inc.

- Praliciguat Phase IIa data to be featured in an oral presentation - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 20, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced that the company will present clinical and preclinical data for the company’s

– Olinciguat Phase II trial in sickle cell disease continues to enroll patients – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 7, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Orphan

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 6, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13 th , 2018 at 4:00 p.m. Pacific Time ( 7:00 p.m.

– Also Evidence of Efficacy in Persistent GERD Patients with Erosive Esophagitis – – Additional Data Presented Further Highlight Role of Bile Acid in Persistent GERD – – Ironwood Expects to Advance IW-3718 into Phase III Trials in 3Q 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun.

Ironwood Shareholders Re-Elect All Three Ironwood Director Nominees CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 31, 2018-- Ironwood Pharmaceuticals , Inc. (NASDAQ: IRWD), a commercial biotech company, today announced that, based on the vote count following the 2018 Annual Meeting of Shareholders,

-  IW-3718 Phase IIb Data Selected for the Distinguished Abstract Plenary Session - CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 23, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced that the company in collaboration with researchers will present